Netherlands Inhalation Devices Market Overview, 2031

Key Insights

• The global inhalation devices market is driven by the vast and rising worldwide burden of chronic respiratory conditions. World Health Organization (WHO) and global epidemiological estimates indicate that over 262 million people live with asthma, while Chronic Obstructive Pulmonary Disease (COPD) affects more than 212 million individuals globally, representing the third leading cause of death worldwide. Conventional manual devices continue to form the baseline of clinical treatment. Among indication segments, asthma accounts for approximately 46% of total device demand due to high prescription refill frequencies for maintenance and rescue therapies.
• A major industry breakthrough currently transforming the pressurized metered-dose inhaler (pMDI) segment is the rapid phase-out of traditional hydrofluoroalkane propellants (HFA-134a and HFA-227ea) in favor of next-generation, low-Global Warming Potential (low-GWP) propellants such as HFO-1234ze and HFC-152a. Because medical pMDIs account for a measurable portion of healthcare-related carbon footprints, global pharmaceutical leaders have achieved major clinical regulatory milestones for carbon-minimal inhalers.
• The market is experiencing a significant technological leap through the development and commercial integration of Internet-of-Things (IoT) smart inhaler modules and breath-actuated digital systems. Equipped with Bluetooth sensors, dose counters, and acoustic inhalation flow monitors, these devices register actuation timing and inspiratory technique quality in real time. Clinical trials demonstrate that digital smart inhaler feedback improves patient medication adherence rates from a baseline average of under 50% up to 80%-90%, significantly reducing acute emergency room visits and hospital readmissions.

Market Outlook

• Supported by the growth of telehealth platforms, remote patient monitoring (RPM) reimbursement models, and digital diagnostic tools, healthcare systems are prioritizing early intervention to manage chronic disease flares outside emergency departments. This shift is fueling sustained adoption of portable, battery-operated vibrating mesh nebulizers, breath-actuated DPIs, and user-friendly digital tracking tools that facilitate self-management among pediatric and elderly demographics.
• Key international societies establishing diagnostic and therapeutic guidelines include the Global Initiative for Asthma (GINA), the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the European Respiratory Society (ERS), and the American Thoracic Society (ATS). The commercial manufacturing landscape is led by prominent global drug delivery developers and medical technology pioneers, including AstraZeneca, GlaxoSmithKline (GSK), Boehringer Ingelheim, Chiesi Farmaceutici, Aptar Pharma, Vectura Group, Kindeva Drug Delivery, Omron Healthcare, and ResMed.

Market Dynamics

Driver: Escalating global burden of chronic respiratory diseases, aging demographics, and expanded outpatient coverage
The primary driver of the global inhalation devices market is the rising worldwide prevalence of chronic respiratory disorders most notably Asthma and Chronic Obstructive Pulmonary Disease (COPD) supported by expanding outpatient healthcare coverage and a rapidly aging population. With over 262 million people living with asthma and more than 212 million affected by COPD globally, chronic airway obstruction represents a major public health challenge and a leading cause of international mortality. Furthermore, accelerating global urbanization, prolonged exposure to atmospheric fine particulate matter, industrial air pollution, and high smoking rates exacerbate structural pulmonary decline, particularly among older adults whose inspiratory mechanics naturally weaken over time.
Challenge: Widespread inhaler non-adherence, poor technique, and multi-jurisdictional regulatory hurdles
A critical challenge impacting the inhalation devices market is the high rate of improper patient usage and non-adherence, paired with complex regulatory requirements for drug-device combination products. Clinical studies consistently indicate that up to 70%-80% of patients fail to operate their inhalation devices correctly, suffering from common errors such as poor hand-breath coordination in pMDIs, insufficient inspiratory flow rate in DPIs, or incomplete breath-holding after actuation. These technique errors result in sub-optimal pulmonary drug deposition, leading to poor disease control, frequent acute exacerbations, and increased emergency room readmissions.
Trend: Accelerating transition to low-GWP eco-friendly propellants and digital IoT smart inhalers
A defining trend reshaping the global inhalation landscape is the simultaneous shift toward environmentally sustainable propellants and the integration of Internet-of-Things (IoT) digital health tracking. To comply with global climate directives (such as the Kigali Amendment to the Montreal Protocol), major pharmaceutical manufacturers are executing a major technical phase-out of traditional hydrofluoroalkane propellants (HFA-134a and HFA-227ea) in favor of next-generation, low-Global Warming Potential (low-GWP) propellants like HFO-1234ze and HFC-152a. These reformulations achieve a carbon footprint reduction of up to 90% per actuation while preserving identical aerosol deposition profiles.

Segment Analysis

Inhalation Devices By Product Type
• The metered dose inhalers market is characterized by the continued importance of portable, rapid, and reproducible aerosol delivery across a broad range of respiratory treatments. MDIs remain particularly useful for patients who benefit from spacer compatibility or require a compact device that can be carried easily during daily activities. Product innovation is increasingly focused on improving actuation consistency, simplifying dose tracking, reducing coordination errors, and developing propellant technologies with lower environmental impact. Manufacturers must also maintain compatibility between the formulation, metering valve, actuator, and container to ensure consistent performance throughout the product's usable life.
• The dry powder inhalers market is distinguished by propellant-free drug delivery and the close relationship between powder formulation, device mechanics, and patient inspiratory effort. Unlike pressurized inhalers, DPIs rely on the patient's inhalation to disperse the medication, making resistance characteristics and powder deaggregation central to effective delivery. Manufacturers are focusing on moisture protection, consistent powder dispersion, intuitive dose-loading systems, and mechanisms that reduce incorrect preparation. Multidose devices can simplify routine treatment, while capsule-based formats offer a different approach to dose handling and formulation design. Digital adherence features and clearer feedback on dose preparation also present opportunities for product differentiation.
• The soft mist inhalers market occupies a specialized position by generating a slowly moving aerosol from a liquid formulation without conventional propellant-driven spray. The slower aerosol plume can reduce coordination demands for certain patients, making SMIs an alternative when the prescribed medicine and the individual's abilities support their use. Their development requires precision engineering to produce a consistent mist, alongside reliable liquid metering and compatibility between the formulation and device components. Manufacturers can differentiate through ergonomic mechanisms, simplified priming procedures, dependable cartridge performance, and clear cleaning instructions.
• The nebulizers market is characterized by its flexibility in delivering compatible liquid medications across hospital, emergency, pediatric, and home-care environments. These systems are particularly valuable when patients cannot use handheld inhalers effectively or when the prescribed formulation is specifically intended for nebulization. Compressor nebulizers provide an established delivery method, while ultrasonic and vibrating-mesh technologies offer alternative approaches to aerosol generation, depending on medication compatibility and clinical requirements. Product differentiation increasingly centers on portability, quieter operation, shorter treatment sessions where achievable, reduced residual medication, and easier cleaning.



Inhalation Devices By Therapeutic Application
• The asthma inhalation devices market is driven by the need to deliver prescribed reliever and controller medications effectively while supporting consistent long-term disease management. Device selection depends on age, inspiratory ability, hand-breath coordination, treatment regimen, and individual preference. MDIs with spacers remain important for children and patients who struggle with coordination, while DPIs and SMIs provide alternatives for appropriately selected individuals. A major area of product differentiation is reducing the gap between device availability and correct use through intuitive operating mechanisms, dose indicators, educational tools, and adherence-support features.
• The COPD inhalation devices market is shaped by the challenges of long-term maintenance treatment, reduced inspiratory capacity in some patients, and the need to accommodate age-related changes in dexterity and coordination. Device selection must account for the patient's ability to generate sufficient inspiratory flow, understand operating instructions, and maintain consistent use. MDIs, DPIs, and SMIs provide different delivery options, while nebulizers may be appropriate for selected patients who cannot use handheld devices effectively or require compatible nebulized medication. Combination inhalers can simplify prescribed regimens when clinically appropriate, creating opportunities for integrated drug-device development. Manufacturers are increasingly differentiating products through ergonomic designs, simplified dose preparation, clear feedback mechanisms, and patient-support programs.
• The others segment of the inhalation devices market encompasses respiratory and pulmonary conditions beyond asthma and COPD, including bronchiectasis, cystic fibrosis, selected respiratory infections, and specialized pulmonary disorders requiring inhaled therapies. These applications can demand particular aerosol characteristics, formulation compatibility, dosing schedules, and equipment-maintenance procedures. Nebulizers are important for selected compatible liquid medicines, including certain inhaled antibiotics and saline formulations, while specialized handheld delivery systems may be used for other therapies. This segment creates opportunities for manufacturers that can develop reliable drug-device combinations tailored to specific clinical requirements rather than relying on general-purpose inhaler designs. Product differentiation depends on precise aerosol generation, compatibility with sensitive formulations, durable components, and clear maintenance instructions.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Inhalation Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Soft Mist Inhalers (SMIs)
• Nebulizers

By Therapeutic Application
• Asthma
• COPD
• Others